Literature DB >> 20307414

Insulin glargine and incidence of cancer--an ongoing debate.

Norbert Hermanns, Bernd Kulzer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20307414      PMCID: PMC2864189          DOI: 10.1177/193229681000400235

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


× No keyword cloud information.
  6 in total

1.  Insulin glargine and cancer: another side to the story?

Authors:  Edwin A M Gale
Journal:  Lancet       Date:  2009-08-15       Impact factor: 79.321

2.  Insulin glargine and malignancy: an unwarranted alarm.

Authors:  Stuart J Pocock; Liam Smeeth
Journal:  Lancet       Date:  2009-07-17       Impact factor: 79.321

3.  Insulin glargine and cancer--an unsubstantiated allegation.

Authors:  Satish K Garg; Irl B Hirsch; Jay S Skyler
Journal:  Diabetes Technol Ther       Date:  2009-08       Impact factor: 6.118

4.  Combined randomised controlled trial experience of malignancies in studies using insulin glargine.

Authors:  P D Home; P Lagarenne
Journal:  Diabetologia       Date:  2009-09-15       Impact factor: 10.122

5.  Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.

Authors:  L G Hemkens; U Grouven; R Bender; C Günster; S Gutschmidt; G W Selke; P T Sawicki
Journal:  Diabetologia       Date:  2009-06-30       Impact factor: 10.122

6.  Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study.

Authors:  J Rosenstock; V Fonseca; J B McGill; M Riddle; J P Hallé; I Hramiak; P Johnston; M Davis
Journal:  Diabetologia       Date:  2009-07-16       Impact factor: 10.122

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.